AdaptHealth ‘stays the course’ for Q1 

CONSHOHOCKEN, Pa. – AdaptHealth reported revenue of $777.9 million for the first quarter of 2025, a decrease of 1.8% compared to the same period last year. 

Net loss attributable to AdaptHealth Corp. was $7.2 million compared to net loss of $2.1 million and adjusted EBITDA was $127.9 million compared to $158.5 million. 

“Amid elevated uncertainty in the external environment, we at AdaptHealth have stayed the course, with a relentless focus on improving our business and providing exceptional service to the 4.2 million patients that depend on us,” said Suzanne Foster, CEO. “Reflecting that focus, we delivered another quarter of solid results, we continued to make progress on our financial position with additional debt reduction, and for a second consecutive quarter, our Diabetes Health segment continued to show signs of improvement. I am excited by the tremendous opportunity ahead, as we continue to leverage our geographic reach, operational scale and patient service excellence to capture market share and drive consistent and sustainable organic growth in each of our four segments.” 

During the quarter, AdaptHealth closed on its previously disclosed agreement to sell certain incontinence assets in its Wellness at Home segment to a third party, and also signed a definitive agreement to sell certain infusion assets in its Wellness at Home segment to a third party, which is expected to close in the second quarter of 2025. 

AdaptHealth is updating previous financial guidance for fiscal year 2025 to account for the disposition of certain incontinence assets, as follows: 

• Net revenue of $3.18 billion to $3.32 billion, from $3.22 billion to $3.36 billion. 
• Adjusted EBITDA of $665 million to $705 million, from $670 million to $710 million. 
• Free cash flow of $180 million to $220 million, unchanged.